3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial-Reference-Cited by-同舟云学术

3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial

Published:2024-04 Issue:10437 Volume:403 Page:1649-1659
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Pérez-García José Manuel,Cortés Javier,Ruiz-Borrego Manuel,Colleoni Marco,Stradella Agostina,Bermejo Begoña,Dalenc Florence,Escrivá-de-Romaní Santiago,Calvo Martínez Lourdes,Ribelles Nuria,Marmé Frederik,Cortés Alfonso,Albacar Cinta,Gebhart Geraldine,Prat Aleix,Kerrou Khaldoun,Schmid Peter,Braga Sofia,Di Cosimo Serena,Gion Maria,Antonarelli Gabriele,Popa Crina,Szostak Emilia,Alcalá-López Daniel,Gener Petra,Rodríguez-Morató Jose,Mina Leonardo,Sampayo-Cordero Miguel,Llombart-Cussac Antonio

Funder

F Hoffmann-La Roche Ltd

Publisher

Elsevier BV

Reference28 articles.

1. Trastuzumab–mechanism of action and use in clinical practice;Hudis;N Engl J Med,2007

2. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis;Cortazar;Lancet,2014

3. Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003)

4. 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO;Gebhart;J Nucl Med,2013

5. Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial;Pérez-García;Lancet Oncol,2021

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance;Nature Reviews Clinical Oncology;2024-09-13

2. ASO Author Reflections: Evolving Multidisciplinary Decision Making for Early-Stage, HER2-Positive Breast Cancer;Annals of Surgical Oncology;2024-09-09

3. Role of [18F]FDG PET/CT in patients with no special type breast cancer: Literature review and comparison between guidelines;The Breast;2024-09

4. The impact of PET imaging on triple negative breast cancer: an updated evidence-based perspective;European Journal of Nuclear Medicine and Molecular Imaging;2024-08-07

5. Molecular Breast Imaging of HER2-Positive Breast Cancer in the Era of PHERGain Trial: The past, the Present, and the Prospects;Cancer Biotherapy and Radiopharmaceuticals;2024-08-01